269 related articles for article (PubMed ID: 24619958)
1. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.
Wang C; Wang L; Su B; Lu N; Song J; Yang X; Fu W; Tan W; Han B
Prostate; 2014 May; 74(7):689-701. PubMed ID: 24619958
[TBL] [Abstract][Full Text] [Related]
2. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG
J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403
[TBL] [Abstract][Full Text] [Related]
3. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
[TBL] [Abstract][Full Text] [Related]
4. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor.
Ozaki N; Ohmuraya M; Hirota M; Ida S; Wang J; Takamori H; Higashiyama S; Baba H; Yamamura K
Mol Cancer Res; 2009 Sep; 7(9):1572-81. PubMed ID: 19737965
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
6. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion.
Cho SH; Park YS; Kim HJ; Kim CH; Lim SW; Huh JW; Lee JH; Kim HR
Int J Oncol; 2012 Jul; 41(1):211-8. PubMed ID: 22552741
[TBL] [Abstract][Full Text] [Related]
7. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
Wang B; Gu Y; Hui K; Huang J; Xu S; Wu S; Li L; Fan J; Wang X; Hsieh JT; He D; Wu K
Urol Oncol; 2018 Oct; 36(10):472.e11-472.e20. PubMed ID: 30139661
[TBL] [Abstract][Full Text] [Related]
8. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.
Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B
Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928
[TBL] [Abstract][Full Text] [Related]
9. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin.
Zuo JH; Zhu W; Li MY; Li XH; Yi H; Zeng GQ; Wan XX; He QY; Li JH; Qu JQ; Chen Y; Xiao ZQ
J Cell Biochem; 2011 Sep; 112(9):2508-17. PubMed ID: 21557297
[TBL] [Abstract][Full Text] [Related]
10. The involvement of FBP1 in prostate cancer cell epithelial mesenchymal transition, invasion and metastasis by regulating the MAPK signaling pathway.
Zhang YP; Liu KL; Yang Z; Lu BS; Qi JC; Han ZW; Yin YW; Zhang M; Chen DM; Wang XW; Li W; Xin H
Cell Cycle; 2019 Oct; 18(19):2432-2446. PubMed ID: 31448674
[TBL] [Abstract][Full Text] [Related]
11. NEDD9 crucially regulates TGF-β-triggered epithelial-mesenchymal transition and cell invasion in prostate cancer cells: involvement in cancer progressiveness.
Morimoto K; Tanaka T; Nitta Y; Ohnishi K; Kawashima H; Nakatani T
Prostate; 2014 Jun; 74(8):901-10. PubMed ID: 24728978
[TBL] [Abstract][Full Text] [Related]
12. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
[TBL] [Abstract][Full Text] [Related]
13. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer.
Yamamichi F; Shigemura K; Behnsawy HM; Meligy FY; Huang WC; Li X; Yamanaka K; Hanioka K; Miyake H; Tanaka K; Kawabata M; Shirakawa T; Fujisawa M
Scand J Urol; 2014 Dec; 48(6):523-32. PubMed ID: 25356787
[TBL] [Abstract][Full Text] [Related]
14. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
15. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
16. Down-regulating ribonuclease inhibitor enhances metastasis of bladder cancer cells through regulating epithelial-mesenchymal transition and ILK signaling pathway.
Xiong D; Liou Y; Shu J; Li D; Zhang L; Chen J
Exp Mol Pathol; 2014 Jun; 96(3):411-21. PubMed ID: 24768914
[TBL] [Abstract][Full Text] [Related]
17. Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway.
Bhat FA; Sharmila G; Balakrishnan S; Arunkumar R; Elumalai P; Suganya S; Raja Singh P; Srinivasan N; Arunakaran J
J Nutr Biochem; 2014 Nov; 25(11):1132-1139. PubMed ID: 25150162
[TBL] [Abstract][Full Text] [Related]
18. The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells.
Zhang Z; Liu ZB; Ren WM; Ye XG; Zhang YY
Int J Mol Med; 2012 Oct; 30(4):856-62. PubMed ID: 22797360
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of SPINK1-positive prostate cancer.
Ateeq B; Tomlins SA; Laxman B; Asangani IA; Cao Q; Cao X; Li Y; Wang X; Feng FY; Pienta KJ; Varambally S; Chinnaiyan AM
Sci Transl Med; 2011 Mar; 3(72):72ra17. PubMed ID: 21368222
[TBL] [Abstract][Full Text] [Related]
20. Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer.
Kolijn K; Verhoef EI; van Leenders GJ
Oncotarget; 2015 Sep; 6(27):24488-98. PubMed ID: 26041890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]